ライフサイエンスコーパス: alpha1-antichymotrypsin

1 or of cytokine signaling-3, lipocalin-2, and alpha1-antichymotrypsin.

2 inhibitors, alpha1-proteinase inhibitor and alpha1-antichymotrypsin.

3 s with raised concentrations (16% higher for alpha1-antichymotrypsin, 18% for alpha1-acid-glycoprotei

4 n to TIGR/MYOC, a serine protease inhibitor (alpha1-antichymotrypsin), a neuroprotective factor (pigm

5 athepsin G can also be completely blocked by alpha1 antichymotrypsin, a specific inhibitor of chymotr

6 alpha1-Antichymotrypsin (AACT) is a major component of t

7 Inhibition of human chymase by the serpins alpha1-antichymotrypsin (ACT) and alpha1-proteinase inhi

8 se (AD) based on immunochemical detection of alpha1-antichymotrypsin (ACT) in amyloid plaques from th

9 omosome 14q32.1 allow a single gene encoding alpha1-antichymotrypsin (ACT) to be expressed in astrocy

10 Additionally, alpha1-antichymotrypsin (ACT), a serpin family inhibitor

11 nd/or that are known to interact with Abeta: alpha1-antichymotrypsin (ACT), interleukin-1beta (IL-1be

12 nes on chromosome 14, presenilin 1 (PS1) and alpha1-antichymotrypsin (ACT), with the risk of sporadic

13 in the liver, including alpha1-antitrypsin, alpha1-antichymotrypsin, alpha-fetal protein, ceruloplas

14 g the pH dependence of the conversion of the alpha1-antichymotrypsin.alpha-chymotrypsin encounter com

15 factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (alpha1-ACT) (1.217, p<0.005), I

16 alpha1-Antichymotrypsin (alpha1-ACT), a member of the se

17 idly bound by protease inhibitors, primarily alpha1-antichymotrypsin, although a fraction is inactiva

18 main protects cathepsin G from inhibition by alpha1-antichymotrypsin and squamous cell carcinoma anti

19 nase inhibitors alpha1-proteinase inhibitor, alpha1-antichymotrypsin, and alpha2-macroglobulin functi

20 ons (ie, cyclin D3, tissue transglutaminase, alpha1-antichymotrypsin, and STAT1), which have not prev

21 eact strongly for desmin, alphaB-crystallin, alpha1-antichymotrypsin, and ubiquitin and variably for

22 orescent derivatives of cysteine variants of alpha1-antichymotrypsin at the P11 and P13 residues.

23 te-phase proteins (alpha1-acid-glycoprotein, alpha1-antichymotrypsin, C-reactive protein, or serum am

24 tion of prostate specific antigen (PSA), PSA-alpha1-antichymotrypsin, carcinoembryonic antigen and mu

25 prothrombin, beta amyloid precursor protein, alpha1-antichymotrypsin, cystic fibrosis transmembrane c

26 hymotrypsin with a fluorescent derivative of alpha1-antichymotrypsin (derivatized at position P7 of t

27 The recombinant PSA was inhibited by alpha1-antichymotrypsin, forming an equimolar complex wi

28 An alpha1-antichymotrypsin-like serpin has been implicated

29 t mice given cathepsin G/chymase inhibitors (alpha1-antichymotrypsin or Z-Gly-Leu-Phe-CH(2)Cl), were

30 f E*I* formation from alpha-chymotrypsin and alpha1-antichymotrypsin using two approaches: first, by

31 Alpha1-antichymotrypsin was a markedly ineffective inhib

32 tio to Abeta of another acute phase protein, alpha1-antichymotrypsin, was not active in preventing fi

33 zyme also is inactivated more effectively by alpha1-antichymotrypsin, which features P1 Leu in the re

34 2A and other isoforms of endopins related to alpha1-antichymotrypsin, yet endopin 2C differs in its t